<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 REPORTING REQUIREMENTS
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) August 31, 2000
---------------
KING PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Tennessee 0-24425 54-1684963
--------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Fifth Street, Bristol, Tennessee 37620
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (423) 989-8000
------------------------
Not Applicable
--------------------------------------------------------------------------------
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 2. ACQUISITION OR DISPOSITION OF ASSETS.
Effective August 31, 2000, King Pharmaceuticals, Inc., a Tennessee
corporation, merged with Jones Pharma Incorporated pursuant to a previously
announced merger of the two companies in a tax-free pooling of interests
transaction. Under the terms of the agreement, Jones shareholders will receive
1.125 shares of King common stock in exchange for each share of Jones common
stock. On August 31, 2000, King issued press releases regarding the approval of
the merger by shareholders of King and Jones and the closing of the merger.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements on Businesses Acquired.
The financial statements required to be filed pursuant to Item 7(a)(1)
are not included with this report. In accordance with Item 7(a)(4), the
Registrant will file such statements no later than November 14, 2000.
(b) Pro Forma Financial Information.
The pro forma financial information required to be filed pursuant to
Item 7(b) is not included with this report. In accordance with Item 7(b)(2), the
Registrant will file such financial information no later than November 14, 2000.
(c) The following exhibits are filed pursuant to Item 601 of Regulation
S-K:
Exhibit
Number Description
------- -----------
99 Press releases of King Pharmaceuticals, Inc. dated August 31,
2000
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KING PHARMACEUTICALS, INC.
Date: September 1, 2000
By: /s/ Brian G. Shrader
-------------------------------------
Brian G. Shrader
Chief Financial Officer
- 1 -
